November 10, 2006

Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk

Key Points

Key points are not available for this paper at this time.

Abstract

An increase in serum GGT predicts onset of metabolic syndrome, incident CVD, and death suggesting that GGT is a marker of metabolic and cardiovascular risk.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Lee et al. (Fri,) studied this question.

synapsesocial.com/papers/69d6c110a0177bf533ed8cc3 https://doi.org/https://doi.org/10.1161/01.atv.0000251993.20372.40

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1γ-Glutamyl transpeptidase: catalytic, structural and functional aspects1981 · 444 citations
2Human Atherosclerotic Plaques Contain Gamma-Glutamyl Transpeptidase Enzyme Activity2004 · 199 citations
3Gamma-glutamyltransferase: Determinants and Association with Mortality from Ischemic Heart Disease and All Causes1995 · 332 citations
4Significant correlation between insulin resistance and serum gamma-glutamyl transpeptidase (gamma-GTP) activity in non-drinkers.2002 · 20 citations
5AN INVESTIGATION OF CORONARY HEART DISEASE IN FAMILIES1979 · 1,671 citations

Bookmark

View Full Paper